Breaking News

Netherlands Defeats Brazil 3-0 World Cup Consolation Game
Tweet TWEET

Wall Street Journal Article Features BIOLASE's Virtually Painless WaterLase Technology

Wall Street Journal Article Features BIOLASE's Virtually Painless WaterLase 
Technology 
BIOLASE's Alternative WaterLase Technology Increases Patient Comfort
by Avoiding Painful Injections of Anesthesia When Compared to
Conventional Dentistry and the Dental Drill 
IRVINE, CA -- (Marketwired) -- 05/01/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading dental laser manufacturer and distributor,
announced today that the patient comfort and clinical benefits of the
Company's revolutionary WaterLase(R) technology was featured in a
Wall Street Journal article, To Cut Tooth Decay: A Laser vs. a Drill,
written by Laura Johannes. The article was published yesterday, April
30, 2013, in the Journal's Health & Wellness section. 
A number of studies on lasers have shown both children and adults can
have cavities filled without the feared, painful, and numbing
injection. A pioneering 2002 study published in the Journal of
Clinical Medicine & Surgery entitled, Clinical Assessment of
Er,Cr:YSGG Laser Application for Cavity Preparation, evaluated 50
cavity preparations using our second-generation Millennium(TM)
WaterLase all-tissue laser. In the study, 94% of the cases were
prepared and treated without anesthesia. No pain was felt in 68% of
the cases and slight pain or tolerable pain was felt in 26% of the
cases, with 6% needing some form of anesthesia. The study concluded
that the WaterLase "is an efficient, effective, and safe device for
caries removal and cavity preparation." Further, the patient
acceptance rate was excellent, and there were no adverse side
effects. 
Federico Pignatelli, Chairman and CEO, said, "The clinical benefits
of our revolutionary WaterLase technology have been well documented
in well over a hundred clinical studies dating back to 1997, and I am
very pleased to now see this technology featured in the prestigious
Wall Street Journal. The key study referenced in the article was
performed in 2002 with our now obsolete, second-generation WaterLase
Millennium all-tissue laser. Our current flagship product, the
WaterLase iPlus(TM), is our fourth-generation all-tissue laser and
its performance far surpasses that of our previous generations. The
iPlus offers far greater power, shorter pulses, and shorter
repetition rates that are adjustable from five to 100 pulses per
second while the Millennium's repetition rate was fixed at 20 pulses
per second. Shorter pulses and lower repetition rates have been
clinically proven to greatly improve patient comfort and allow for no
anesthesia." 
"Back in 2007, a multi-site clinical study commissioned and funded by
BIOLASE was performed in order to evaluate the improvement in patient
comfort levels in cavity preparations resulting from the range of new
pulse settings introduced with the third-generation WaterLase MD(R).
The data from this unpublished compilation demonstrated that no
anesthesia is required in the vast majority of cavity preparation
classes and procedures. Of the 159 cavity preparation procedures in
the study, 157 did not require an injection of anesthesia, a 99%
success rate, and patients experienced more comfort at the lower
repetition rates. The range of settings was further improved and
expanded with the introduction of the WaterLase iPlus in 2011,"
concluded Pignatelli. 
"The 2002 study referenced in the Journal article certainly
demonstrated excellent clinical results, but the Millennium would be
considered slow by today's WaterLase standards," said Dr. Tim Kelly,
DDS, a current WaterLase iPlus owner and doctor involved in the 2007
multi-center study. "The WaterLase iPlus is a tremendous improvement
over previous generations of WaterLase with twice the power of the MD
Turbo and wider range of pulse settings and lower repetition rates.
The evolution in WaterLase technology and significantly advanced
clinical techniques developed over the past decade have resulted in
radically improved clinical results, less time in the chair for
patients, less stress for the dentist dealing with relaxed patients,
and far greater patient comfort." 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures and markets dental lasers and also distributes
and markets dental imaging equipment; products that are focused on
technologies that advance the practice of dentistry and medicine. The
Company's laser products incorporate over 340 patented and
patent-pending technologies designed to provide biologically
clinically superior performance with less pain and faster recovery
times. Its imaging products provide cutting-edge technology at
competitive prices to deliver the best results for dentists and
patients. BIOLASE's principal products are dental laser systems that
perform a broad range of dental procedures, including cosmetic and
complex surgical applications, and a full line of dental imaging
equipment. BIOLASE has sold more than 22,000 lasers.  
Other products under development address ophthalmology and other
medical and consumer markets. 
WaterLase(R), WaterLase MD(R), iPlus(R), WaterLase MD Turbo(TM), and
WaterLase Millennium(TM) are trademarks of BIOLASE, Inc.  
Please refer to the Company's website for the 2002 study, Clinical
Assessment of Er,Cr:YSGG Laser Application for Cavity Preparation. 
For updates and information on WaterLase and laser dentistry, find
BIOLASE online at www.biolase.com, Facebook at
www.facebook.com/biolaseinc, Twitter at www.twitter.com/biolaseinc,
Pinterest at www.pinterest.com/biolase, Linkedin at
www.linkedin.com/company/biolase, Instagram at
www.instagram.com/biolaseinc and YouTube at
www.youtube.com/biolasevideos.  
For further information, please contact: 
Michael Porter 
Porter, LeVay & Rose, Inc. 
212-564-4700